




ARCUTIS
BIOTHERAPEUTICS

Bioscience applied to the skin.



ZORYVE[®] (roflumilast)
Topical Foam 0.3% for
Scalp and Body Psoriasis
Launch Call

June 2, 2025



Today's Speakers



Frank Watanabe
President & CEO



Patrick Burnett, MD, PhD, FAAD
Chief Medical Officer



Tina Bhutani, MD, MAS, FAAD
Board Certified Dermatologist,
Clinical Researcher, and CEO of
Synergy Dermatology



Todd Edwards
Chief Commercial Officer

Legal Disclaimers

This presentation and the accompanying oral presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning our current and future financial performance, business plans and objectives, current and future clinical and preclinical development activities, current and future commercialization activities (including payer coverage), timing and success of our ongoing and planned clinical trials and related data, the timing of announcements, updates and results of our clinical trials and related data, timing of submissions and our ability to obtain and maintain regulatory approval, the potential therapeutic benefits and economic value of our product candidates, competitive position, industry environment, and potential market opportunities.

Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to management. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors including, but not limited to, those related to the success, cost and timing of our product candidate development activities and ongoing and planned clinical trials; our plans to develop and commercialize targeted therapeutics, including our lead product candidates roflumilast cream and roflumilast foam; the progress of patient enrollment and dosing in our clinical trials; the ability of our product candidates to achieve applicable endpoints in the clinical trials; the safety profile of our product candidates; the potential for data from our clinical trials to support a marketing application, as well as the timing of these events; our ability to obtain funding for our operations, development and commercialization of our product candidates; the timing of submissions and our ability to obtain and maintain regulatory approvals; the rate and degree of market acceptance and clinical utility of our product candidates; the size and growth potential of the markets for our product candidates, and our ability to serve

those markets; our commercialization, marketing and manufacturing capabilities and strategy; current and future agreements with third parties in connection with the commercialization of our product candidates; the timing and our ability to obtain and maintain quality payer coverage; the management of gross-to-net; our expectations regarding our ability to obtain and maintain intellectual property protection; our dependence on third party manufacturers; the success of competing therapies that are or may become available; our ability to attract and retain key scientific or management personnel; our ability to identify additional product candidates with significant commercial potential consistent with our commercial objectives; and our estimates regarding expenses, future revenue, gross-to-net, capital requirements and needs for additional financing. For a further description of the risks and uncertainties applicable to our business, see the "Risk Factors" section of our most recent annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC), as well as any subsequent filings.

Moreover, we operate in a very competitive and rapidly changing environment, and new risks may emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed herein may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

You should not rely upon forward-looking statements as predictions of future events. Although our management believes that the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances described in the forward-looking statements will be achieved or occur. Any forward-looking statement that we make in this presentation or

the accompanying oral presentation are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of such statement. Except as required by law, we undertake no obligation to revise or update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments, or otherwise.

This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. Neither we nor any other person makes any representation as to the accuracy or completeness of such data or undertakes any obligation to update such data after the date of this presentation. In addition, projections, assumptions, and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.

For further information with respect to Arcutis, we refer you to our most recent annual report on Form 10-K, as amended, and our most recent quarterly report on Form 10-Q, filed with the SEC. In addition, we are subject to the information and reporting requirements of the Securities Exchange Act of 1934 and, accordingly, we file periodic reports, current reports, proxy statements and other information with the SEC. These periodic reports, current reports, proxy statements and other information are available for review at the SEC's website at <http://www.sec.gov>.

All product and company names are trademarks™ or registered® trademarks of their respective holders.

Speakers & Agenda



Frank Watanabe
President & CEO

Introduction

ZORYVE Foam - Differentiated Clinical Profile

Patient Testimonial

Clinician Experience with Plaque Psoriasis

Commercial Execution

Q&A



Building a Segment-Leading Franchise

Expect sustained revenue growth & increased operational leverage as we grow ZORYVE® franchise and build out the pipeline

5th FDA approval of ZORYVE, the first and only branded topical foam and cream for psoriasis

ZORYVE is the **# 1 prescribed** branded topical for three major inflammatory skin conditions

Targeted approach for **conversion** of **topical steroid** prescriptions to ZORYVE

Strong growth in Q1 2025 across our portfolio, 10% sequential volume growth, & expect continued growth in 2025

sNDA = supplemental New Drug Application

Speakers & Agenda



Patrick Burnett, MD, PhD, FAAD
Chief Medical Officer

Introduction

ZORYVE Foam - Differentiated Clinical Profile

Patient Testimonial

Clinician Experience with Plaque Psoriasis

Commercial Execution

Q&A



ZORYVE (Roflumilast) Topical Foam 0.3% for Scalp and Body Psoriasis

**ZORYVE
foam effectively
clears psoriasis
and simplifies
treatment**

**Once daily foam
for use on all hair
and skin types for
any duration**

**Single treatment
for all areas of
the body, an
alternative to
steroids**

**Rapid and robust
reduction of itch**



ZORYVE Foam: FDA-Approved Label Supports Broad Use

Z ZORYVE[®] (roflumilast) topical foam, 0.3%

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use ZORYVE foam, 0.3%, safely and effectively. See full prescribing information for ZORYVE foam, 0.3%.

ZORYVE[®] (roflumilast) topical foam, 0.3%
Initial U.S. Approval: 2011

-----RECENT MAJOR CHANGES-----

Indications and Usage, Plaque Psoriasis (1.2) 5/2025

-----INDICATIONS AND USAGE-----

ZORYVE topical foam, 0.3%, is a phosphodiesterase 4 inhibitor indicated for the treatment of

- seborrheic dermatitis in adult and pediatric patients 9 years of age and older. (1.1)
- plaque psoriasis of the scalp and body in adult and pediatric patients 12 years of age and older. (1.2)

-----DOSAGE AND ADMINISTRATION-----

- Apply once daily to affected areas. (2)
- For topical use only. Not for ophthalmic, oral, or intravaginal use. (2)

-----DOSAGE FORMS AND STRENGTHS-----

Topical foam, 0.3%: 3 mg of roflumilast per gram in 60-gram pressurized cans. (3)

-----CONTRAINDICATIONS-----

Moderate to severe liver impairment (Child-Pugh B or C). (4)



Indicated for treatment of plaque psoriasis



Approved for ages 12+



Itch improvement data included in label




Once daily use



No limitation on severity, body part, area, or duration

ZORYVE Foam Rapidly Clears Scalp and Body Psoriasis at Week 8





Multiple imputation of missing data.

^aNominal P value.

CI: confidence interval. Data sourced from ARRECTOR - FDA approval was based on both ARRECTOR and Trial 204.

Significantly More Patients Treated with ZORYVE Foam Had Improvement in Itch at Week 8




^aSI-NRS score of 0 or 1 evaluated in patients with baseline SI-NRS ≥ 2 .

^bWI-NRS score of 0 or 1 evaluated in patients with baseline WI-NRS ≥ 2 .

CI: confidence interval.

Data sourced from ARRECTOR - FDA approval was based on both ARRECTOR and Trial 204.

Greater Improvement in Scalp Itch Within 24 Hours



Data sourced from ARRECTOR - FDA approval was based on both ARRECTOR and Trial 204.

Significant and Rapid Clearance: Both Scalp and Body

Baseline S-IGA=4



Week 2 S-IGA=3



Week 8 S-IGA=1



Baseline B-IGA=2



Week 2 B-IGA=2



Week 8 B-IGA=1



56 yr old male, black/African American ; 56 yr old male, white. Individual patient results may vary

ZORYVE Foam was Very Well Tolerated

Adverse Events Occurring in > 1% of Subjects

Preferred Term	ZORYVE 0.3% (n=479)	Vehicle (n=255)
Headache	15 (3.1%)	3 (1.2%)
Diarrhea	12 (2.5%)	4 (1.6%)
Nausea	8 (1.7%)	0 (0.0%)
Nasopharyngitis	6 (1.3%)	2 (0.8%)

AE: adverse event; SAE: serious adverse event; TEAE: treatment-emergent adverse event

Pooled data from Trial 204 and ARRECTOR

Patient Testimonial



Lori O.
Patient Ambassador

Introduction

ZORYVE Foam - Differentiated Clinical Profile

Patient Testimonial

Clinician Experience with Plaque Psoriasis

Commercial Execution

Q&A



Speakers & Agenda



Tina Bhutani, MD, MAS, FAAD

Board Certified Dermatologist,
Clinical Researcher, and
CEO of Synergy Dermatology

Introduction

ZORYVE Foam - Differentiated Clinical Profile

Patient Testimonial

Clinician Experience with Plaque Psoriasis

Commercial Execution

Q&A



Plaque Psoriasis Overview

Plaque psoriasis is a common, chronic, inflammatory skin disease that occurs in approximately 9 million people in the United States

Characterized by “plaques,” or raised, red areas of skin covered with a silver or white layer of dead skin cells

Can appear anywhere on the body, including:^{1,2}

- Scalp
- Knees, elbows, torso
- High impact areas like face and genitals
- Intertriginous areas like armpits, under breasts, stomach folds


Itch and pain: important drivers of quality-of-life burden



1. The National Psoriasis Foundation 2. National Institute of Arthritis and Musculoskeletal and Skin Diseases.

Mental Health and Social Burden of Psoriasis

Symptom Locations That Have Greatest Impact on Quality of Life




2021 Harris Poll nationwide survey of 507 patients with psoriasis

15 - 20%


Patients with psoriasis experience depression (twice as likely as general population)




3 in 4 agree that dealing with psoriasis symptoms made them feel:



Embarrassed



Anxious



Depressed

Treating Psoriasis Locations Present Unique Challenges

Sensitive Areas

Face:


- More easily irritated
- Thin skin areas, greater drug absorption
- Cataract and glaucoma are risks of steroid use on or around eyes

Intertriginous:

- More easily irritated
- Thin skin, greater drug absorption
- Risk of atrophy/striae

Genital:

- More easily irritated
- Thin skin, greater drug absorption
- Skin can become permanently damaged with certain treatments



Difficult to Treat Areas

Scalp:

- Difficult to deliver drug to skin
- Can't use creams or ointments
- Effect on hair care routine can impact compliance

Elbows/Knees:

- Harder to treat with topicals

Speakers & Agenda



Todd Edwards
Chief Commercial Officer

Introduction

ZORYVE Foam - Differentiated Clinical Profile

Patient Testimonial

Clinician Experience with Plaque Psoriasis

Commercial Execution

Q&A



Plaque Psoriasis Often Appears in Both Hair-Bearing and Non-Hair-Bearing Areas



~50% of patients with psoriasis present with scalp involvement

Up to 80% of patients with scalp psoriasis have involvement in other body areas



~49% of patients have facial involvement



~30% of patients have involvement in folds, such as axilla, groin, intergluteal cleft, and external genitalia


ZORYVE Foam Reduces Need for Polypharmacy in Scalp and Body Psoriasis

Treatment with ointments, creams, and shampoos can be effective; however, HCPs and patients share that different skin types and areas of the body **benefit from additional formulation** options

Foams are more **desired** and remain an unmet need as no product has delivered on the **combination of powerful efficacy, favorable tolerability and ease of application**



Psoriasis patients use an average of 6 products per day



ZORYVE foam single solution

One foam. Once a day. Anywhere.

ZORYVE Foam Already in Distribution



HCP relationships in place
Field already promoting



Contracted Pharmacy Network already dispensing
Familiar with co-pay card



Patient Access seamless with established network
Available at pharmacies


ZORYVE Foam listed in
key EMR platforms

ZORYVE patient access
established

Drive increased volume of
covered prescriptions

Ongoing work with
downstream health plans

ZORYVE Offers a Differentiated Value Proposition in Plaque Psoriasis



Plaque psoriasis is a chronic, inflammatory skin disease that occurs in approximately **nine million people** in the United States

Topically Eligible Patients with Psoriasis Have Comprehensive Treatment Options with **ZORYVE**



ZORYVE. Once a day. Anywhere.

ZORYVE is Unique in Dermatology, With Multiple Formulations and Indications

Plaque Psoriasis

Seborrheic Dermatitis

Atopic Dermatitis

9M Patients

10M Patients

26M Patients

ZORYVE 0.3%

ZORYVE 0.15%

Cream

Foam

Cream

Rapid, Reliable Relief Anywhere

Rapid Itch Relief


Once-daily steroid-free topical
Safety and tolerability enables treatment in any location for any duration

Simple, predictable access

One co-pay card

Efficient & consistent fulfillment process

As HCPs Continue to Adopt the ZORYVE Portfolio Their Prescriptions Increase Substantially



Xponent data rolling thirteen weeks (R13W) Feb 2025. U.S sales and Arcutis targets only

Thank You



Frank Watanabe
President & CEO



Todd Edwards
Chief Commercial
Officer



**Patrick Burnett,
MD, PhD, FAAD**
Chief Medical Officer



Latha Vairavan
Chief Financial Officer



**Tina Bhutani, MD, MAS,
FAAD**
Board Certified Dermatologist,
Clinical Researcher, and CEO of
Synergy Dermatology

Introduction

ZORYVE Foam - Differentiated Clinical Profile

Patient Testimonial

Clinician Experience with Plaque Psoriasis

Commercial Execution

Q&A

